NRG Oncology Semiannual Meeting - Jan 25, 2019 - Pres time: Feb 8, 2019; "Friday, February 8, 2019, 8:05 – 8:17 am, NRG Oncology Phase II Randomized Trial of nivolumab with or without Ipilimumab in patients with persistent or recurrent ovarian cancer; Saturday, February 9, 2019, 8: 45 AM - 9:00 AM, Active Phase I Studies (including safety lead-ins): NRG-GY007 A phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer; 170R A phase II evaluation of dalantercept, a novel soluble recombinant activin receptor-like kinase 1 (ALK-1) inhibitor receptorfusion protein, in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma; February 9, 2019, 10:00 AM – 12:00 PM, NRG-GY007; February 8-9, 2019, 8:00 am - 10:00 am, GOG0218 A Phase III trial of carboplatin and paclitaxel...primary peritoneal or fallopian tube cancer; Review of Active Studies: NRG-GY007; Activated for Phase I..."
CME
|